1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd.

603259.SS
WuXi AppTec Co., Ltd.CN flagShanghai Stock Exchange
118.30
CNY
-4.67
- -
292.59BMarket Cap
WuXi AppTec Co., Ltd.
603259.SS
(Shanghai Stock Exchange)

Recent

price

118.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.95
2.32
2.88
3.52
4.03
4.69
5.92
7.86
13.44
13.73
13.62
15.9
12.37
Revenue per Share
0.22
0.17
0.46
0.56
0.95
0.68
1.06
1.75
3.01
3.27
3.28
6.7
5.68
Basic EPS, GAAP
-0.3
-0.09
0.38
0.2
-0.25
0.14
0.34
-0.81
0.22
2.68
2.92
4.08
-1.55
Free Cash Flow per Basic Share
0.01
0.02
0.02
0.02
0.03
0.27
0.23
0.31
0.55
0.94
1.07
1.74
1.33
Dividend per Share
0.79
0.82
0.92
1.56
2.44
2.7
3.77
5.18
7.55
9.78
12.11
17.19
18.38
Book Value per Share
2.15
2.79
2.55
2.52
6.85
5.51
10.86
12.1
14.79
17.64
19.62
27.32
28.25
Tangible Book Value per Share
2,128
2,105
2,123
2,203
2,388
2,747
2,793
2,913
2,928
2,938
2,881
2,858
2,925
Basic Weighted Avg Shares
4,140
4,883
6,116
7,765
9,614
12,872
16,535
22,902
39,355
40,341
39,241
45,456
36,180
Sales/Revenue/Turnover
16.73
10.36
20.27
22.71
20.45
20.36
20.16
20.35
24.77
29.17
29.59
37.41
39.1
Operating Margin (%)
- -
327
345
403
544
841
1,003
1,286
1,693
2,284
2,782
3,474
- -
Depreciation Expense
462
349
975
1,227
2,261
1,855
2,960
5,097
8,814
9,607
9,450
19,151
16,616
Net Income, GAAP
16.58
14.67
18.9
18.58
9.58
18.21
11.37
14.62
16.16
18.02
17.09
19.13
16.72
Effective Tax Rate (%)
11.15
7.15
15.94
15.8
23.51
14.41
17.9
22.26
22.4
23.81
24.08
42.13
45.92
Profit Margin (%)
2,345
3,365
1,839
845
7,883
6,029
15,139
9,001
9,498
15,666
22,464
42,442
46,128
Working Capital
87
- -
- -
300
644
3,742
2,886
1,626
1,765
1,786
3,506
2,274
2,237
LT Debt
4,903
6,430
6,062
6,927
18,136
17,410
32,718
38,757
46,927
55,517
59,086
80,248
84,772
Total Equity
- -
6.69
14.47
18.03
12.57
10.02
9.75
9.85
16.85
16.66
15.15
17.66
14.15
Return on Invested Capital (%)
- -
0.76
21.37
28.52
35.14
18.4
21.99
29.8
36.96
30.61
25.4
39.04
30.91
Return on Capital (%)
- -
20.48
53.17
45.62
48.85
27.99
32.97
39.8
47.41
37.79
29.7
45.58
35.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
6,146
6,142
LT Borrowings
- -
1,819
1,819
LT Finance Leases
- -
455
418
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
2,984
2,984
Market Capitalization
318,891
258,005
286,990

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
61,677
65,169
Cash, Cash Equivalents & STI
- -
40,938
43,384
Accounts Receivable, Net
- -
7,263
7,701
Inventories
- -
8,993
9,966
Total Current Liabilities
- -
19,235
19,041
Payables & Accruals
- -
- -
- -
ST Debt
- -
6,146
6,142
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.44%
20.02%
35.82%
Free Cash Flow
-14.63%
135.82%
38.82%
Net Income, GAAP
58.63%
51.02%
102.65%
Sales/Revenue/Turnover
26.43%
25.19%
15.84%
Total Cash Common Dividend
115.4%
52.71%
61.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,982
9,259
10,461
11,539
39,241
2025
9,655
11,145
- -
12,599
45,456
2026
12,436
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.67
- -
- -
- -
3.28
2025
1.29
- -
- -
- -
6.7
2026
1.59
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
1.07
2025
0.02
- -
- -
- -
1.74
2026
0.01
- -
- -
- -
- -
Similar Companies
AccuStem Sciences Limited (ACMSY)
Microba Life Sciences Limited (MAP.AX)
Welgene Biotech Co.,Ltd. (6661.TWO)
WuXi AppTec Co., Ltd. (603259.SS)
Epigenomics AG N (ECX.F)
IDEXX Laboratories, Inc. (IDXX)
Business
WuXi AppTec Co., Ltd. (603259.SS) is a leading global contract research, development, and manufacturing organization (CRDMO) that provides integrated end-to-end R&D and manufacturing services to the pharmaceutical, biotechnology, and life sciences industries; its core offerings span WuXi Chemistry for small molecule drug discovery, process development, and API manufacturing; WuXi Biology for target identification, hit-to-lead optimization, and candidate selection across small molecules, biologics, peptides, and oligonucleotides; WuXi Testing for preclinical safety assessments, bioanalysis, DMPK studies, and formulation development; and advanced solutions including Laboratory Testing Division services for drug and medical device testing from preclinical to clinical stages. Founded in 2000 and headquartered in Shanghai, China, the company operates approximately 20 research and manufacturing sites across Asia, Europe, and North America, including major hubs in the United States, Germany, Switzerland, and Singapore, serving nearly 6,000 customers from over 30 countries such as GlaxoSmithKline, AstraZeneca, Pfizer, and Jiangsu Hengrui with around 39,000 employees as of 2025. In recent developments, WuXi AppTec signed a definitive agreement in December 2024 to sell its U.S. and U.K.-based WuXi Advanced Therapies (cell and gene therapy CTDMO) unit to Altaris, LLC, with the transaction expected to close in the first half of 2025; divested its U.S. medical device testing operations in Minnesota and Georgia to NAMSA in January 2025; and reached a definitive agreement in October 2025 with Hillhouse Investment Management to sell its China-based clinical research services, including WuXi Clinical (CRO) and WuXi MedKey (SMO), to sharpen focus on its core CRDMO platform comprising WuXi Chemistry, Biology, and Testing; additionally, its Changzhou and Taixing API sites passed FDA inspections without observations in March 2025, and it completed a second RMB1.0 billion A-share repurchase program in August 2025.